ES2176331T3 - Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia. - Google Patents

Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.

Info

Publication number
ES2176331T3
ES2176331T3 ES95924223T ES95924223T ES2176331T3 ES 2176331 T3 ES2176331 T3 ES 2176331T3 ES 95924223 T ES95924223 T ES 95924223T ES 95924223 T ES95924223 T ES 95924223T ES 2176331 T3 ES2176331 T3 ES 2176331T3
Authority
ES
Spain
Prior art keywords
pct
treatment
schisophrenia
sec
date
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95924223T
Other languages
English (en)
Inventor
Meir Shinitzky
Michael Deckmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Application granted granted Critical
Publication of ES2176331T3 publication Critical patent/ES2176331T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION HACE REFERENCIA A UNA COMPOSICION FARMACEUTICA PARA EL TRATAMIENTO DE TRASTORNOS ESQUIZOFRENICOS QUE INCLUYE UN VEHICULO ACEPTABLE FARMACEUTICAMENTE Y COMO INGREDIENTE ACTIVO UN AGENTE INMUNOSUPRESOR
ES95924223T 1994-06-13 1995-06-13 Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia. Expired - Lifetime ES2176331T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11001194A IL110011A (en) 1994-06-13 1994-06-13 Pharmacological preparations for the treatment of schizophrenia

Publications (1)

Publication Number Publication Date
ES2176331T3 true ES2176331T3 (es) 2002-12-01

Family

ID=11066236

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95924223T Expired - Lifetime ES2176331T3 (es) 1994-06-13 1995-06-13 Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.

Country Status (11)

Country Link
US (1) US5912250A (es)
EP (1) EP0772442B1 (es)
JP (1) JPH10501257A (es)
AT (1) ATE216891T1 (es)
AU (1) AU704355B2 (es)
BR (1) BR9508021A (es)
CA (1) CA2192822C (es)
DE (1) DE69526584T2 (es)
ES (1) ES2176331T3 (es)
IL (1) IL110011A (es)
WO (1) WO1995034306A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1103699A (en) * 1997-10-17 1999-05-10 Rockefeller University, The Use of an inhibitor of the dephosphorylation of darpp-32 for treating schizophrenia
US6013621A (en) * 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
US6204245B1 (en) * 1999-09-17 2001-03-20 The Regents Of The University Of California Treatment of narcolepsy with immunosuppressants
US7112566B1 (en) * 1999-09-17 2006-09-26 The Regents Of The University Of California Systemic administration of Hypocretin-1
EP1535616B1 (en) 2002-08-22 2009-05-13 Dainippon Sumitomo Pharma Co., Ltd. Remedy for integration dysfunction syndrome
WO2004113333A1 (ja) 2003-06-23 2004-12-29 Dainippon Sumitomo Pharma Co., Ltd. 老人性痴呆症治療剤
WO2005080976A1 (ja) 2004-02-20 2005-09-01 Dainippon Sumitomo Pharma Co., Ltd. 統合失調症の記憶・学習機能障害治療薬のin vivoスクリーニング方法
US20100112600A1 (en) * 2006-07-13 2010-05-06 Azard Bonni Methods and compositions for modulating synapse formation
US8258139B2 (en) 2010-11-08 2012-09-04 Dainippon Sumitomo Pharma Co., Ltd. Method of treatment for mental disorders

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9203814D0 (en) * 1992-02-21 1992-04-08 Univ London Treatment of long term auto-immune conditions

Also Published As

Publication number Publication date
JPH10501257A (ja) 1998-02-03
ATE216891T1 (de) 2002-05-15
CA2192822C (en) 2007-04-03
DE69526584D1 (de) 2002-06-06
BR9508021A (pt) 2004-04-20
DE69526584T2 (de) 2002-11-14
WO1995034306A1 (en) 1995-12-21
EP0772442A1 (en) 1997-05-14
IL110011A (en) 2004-09-27
EP0772442B1 (en) 2002-05-02
CA2192822A1 (en) 1995-12-21
AU2881995A (en) 1996-01-05
AU704355B2 (en) 1999-04-22
IL110011A0 (en) 1994-10-07
US5912250A (en) 1999-06-15

Similar Documents

Publication Publication Date Title
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
DK0668863T3 (da) Quinuclidinderivat som substans P-antagonist
BR9912975A (pt) Composto e composições para liberação de agentes ativos, método para sua obtenção e seu uso
DE59511002D1 (de) Wirkstoffe für die behandlung der senilen xerosis und zubereitungen
GEP20012388B (en) Metalloproteinase Inhibitors, Pharmaceutical Compositions on Their Base, Use and Methods for Obtaining and Intermediates
MY129356A (en) Electrospun pharmaceutical compositions
ECSP941122A (es) Derivados de 5-arilindoles
MX9307885A (es) Aplicacion de la carbamzaepina y oxcarbazepian para la obtencion de medicamentos para el tratamiento de la enfermedad de parkinson y los sindromes parkinsonianos.
ES2094034T3 (es) Composicion antiacneica para el tratamiento simultaneo de las capas superficiales y profundas de la piel, su utilizacion.
BG105568A (en) Pharmaceutical compositions for modified release of an insulin sensitiser and another antidiabetic agent
PA8485601A1 (es) Azalidas de 13 miembros y su uso como agentes antibioticos.
MX9301197A (es) Derivados de indol.
TW324662B (en) Benzamide-containing pharmaceutical composition
ES2176331T3 (es) Uso de agentes inmunosupresores para el tratamiento de la esquizofrenia.
ATE186210T1 (de) Heterofunktionelle mucoadhäsive galenische zusammensetzung
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
MX9403088A (es) Composiciones farmaceuticas que contienen deriva- dos de indol y metodos de uso.
SE9702563D0 (sv) Compounds
ES2111352T3 (es) Uso de diester fosfato para el tratamiento de enfermedades retinianas.
BR9814495A (pt) Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo
DK0713386T3 (da) Sprayformulering med kølende effekt
ES2175153T3 (es) Uso de inhibidores de colinesterasa para la fabricacion de un medicamento para el tratamiento de la xerostomia.
ES2157984T3 (es) Utilizacion de 4'-yodo-4'-desoxidoxorrubicina para el tratamiento de la amidoidosis.
DK0742716T3 (da) Farmaceutisk sammensætning til systemisk transdermal indgivelse med det aktive middel morphin-6-glucuronid
ES2184121T3 (es) Formulacion para el tratamiento y/o profilaxis de la demencia.